S SENSIBLE BIOTECHNOLOGIES
LIVE

Serial Number

79380667

Owner

Sensible Biotechnologies s. r. o.

Attorney

Marek Krizka

Filing Date

Jun 1, 2023

Add to watchlist:

No watchlists yet
View on USPTO

S SENSIBLE BIOTECHNOLOGIES Trademark

Serial Number: 79380667 • Registration: 8226479

S SENSIBLE BIOTECHNOLOGIES is a trademark filed by Sensible Biotechnologies s. r. o. on June 1, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Sensible Biotechnologies s. r. o.

Svätoplukova 30

Entity Type: 16

Trademark Details

Filing Date

June 1, 2023

Registration Date

April 28, 2026

Published for Opposition

March 10, 2026

Goods & Services

Biotechnology testing of pharmaceutical preparations for gene therapy, pharmaceuticals, chemicals and cell culture media; consulting services in the field of biotechnology; research and development in the pharmaceutical and biotechnology fields; writing of computer programs for biotechnological applications; development of measuring probes for biotechnological applications; research and development of new products in the field of biotechnology; designing equipment for the biotechnology industry; providing information on the subject of scientific research in the field of biochemistry and biotechnology; research in the field of cell engineering technology; cell culture services for scientific and research purposes, for others; analysis in the field of molecular biology, namely, messenger RNA analysis to diagnose and treat diseases like COVID-19, influenza, RSV, Zika, CMV, HIV, melanoma, lung cancer, pancreatic cancer, cystic fibrosis, propionic acidemia, methylmalonic acidemia, Fabry disease, Gaucher disease, heart disease, multiple sclerosis, Type 1 diabetes, rheumatoid arthritis, and various allergies; research relating to molecular sciences; contract research services relating to molecular sciences; microbiological testing of cell culture media, DNA and RNA to diagnose and treat diseases like COVID-19, influenza, RSV, Zika, CMV, HIV, melanoma, lung cancer, pancreatic cancer, cystic fibrosis, propionic acidemia, methylmalonic acidemia, Fabry disease, Gaucher disease, heart disease, multiple sclerosis, Type 1 diabetes, rheumatoid arthritis, and various allergies medical research; pharmaceutical research; biochemical analyses; biochemical research and development services in the field of messenger RNA to diagnose and treat diseases like COVID-19, influenza, RSV, Zika, CMV, HIV, melanoma, lung cancer, pancreatic cancer, cystic fibrosis, propionic acidemia, methylmalonic acidemia, Fabry disease, Gaucher disease, heart disease, multiple sclerosis, Type 1 diabetes, rheumatoid arthritis, and various allergies; laboratory analyses of materials, namely, DNA and RNA materials to diagnose and treat diseases like COVID-19, influenza, RSV, Zika, CMV, HIV, melanoma, lung cancer, pancreatic cancer, cystic fibrosis, propionic acidemia, methylmalonic acidemia, Fabry disease, Gaucher disease, heart disease, multiple sclerosis, Type 1 diabetes, rheumatoid arthritis, and various allergies; biochemical research; biochemical analysis; biochemical research and development; biological laboratory research; chemical laboratory research; laboratory testing of materials; laboratory research in the field of chemistry; DNA testing for scientific research purposes, namely, DNA screening, determining DNA mutations; chemical laboratory services; biological research laboratory services; genetic engineering services in the field of genetic diseases; chemical analysis; scientific research in the field of genetics and genetic engineering; research and development in the field of microorganisms and cells

Chemicals for use in biotechnological manufacturing processes; chemicals for use in biotechnological product development; enzymes derived from biotechnological processes for use in industry; cell culture media for use in the biotechnological industry for scientific and research use; cell culture reagents for scientific and research use; biological preparation for use in cell cultures other than for medical or veterinary use; chemical for use in biotechnological manufacturing processes for use in molecular separation processes other than for medical or veterinary use; chemical for use in biotechnological product development for use in molecular separation processes other than for medical or veterinary use; cultures of microbiotic organisms, other than for medical use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; cell culture media for microbiology for scientific and research purposes; biological preparations for use in science; biological preparations for use in industry; biological preparations for use in cell cultures, other than for medical or veterinary purposes

Retail store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; wholesale store services for pharmaceutical, veterinary and sanitary preparations and medical supplies

Biotechnological preparations for use in cell cultures for medical purposes; cells for medical use; living cells for medical use

Filing History

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 28, 2026 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 28, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 28, 2026 R.PR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 12, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 12, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 12, 2026 REAP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 10, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 10, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 4, 2026 NONP
WITHDRAWN FROM PUB - OG REVIEW QUERY
Feb 10, 2026 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 24, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 24, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 24, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 24, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 24, 2026 CNEA
NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
Jul 7, 2025 RDX3
ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
Jul 7, 2025 RDX1
ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
Jul 7, 2025 RRDX
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 23, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 23, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 23, 2025 ERFR
NEW REPRESENTATIVE AT IB RECEIVED
Apr 4, 2025 NREP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 29, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 11, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 11, 2025 OPNR
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 23, 2024 GNFN
FINAL REFUSAL E-MAILED
Oct 23, 2024 GNFR
FINAL REFUSAL WRITTEN
Oct 23, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 11, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 11, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 11, 2024 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 10, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sep 10, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sep 10, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 10, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 10, 2024 COAR
REFUSAL PROCESSED BY IB
Apr 8, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 19, 2024 RFCS
REFUSAL PROCESSED BY MPU
Mar 18, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 25, 2024 RFCR
NON-FINAL ACTION WRITTEN
Feb 24, 2024 CNRT
ASSIGNED TO EXAMINER
Feb 23, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 24, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 18, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 12, 2023 REPR